Top-Rated Stocks NASDAQ:EXEL Exelixis - EXEL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $17.62 +0.23 (+1.32%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$17.34▼$17.6550-Day Range$15.41▼$17.7152-Week Range$14.87▼$23.40Volume2.54 million shsAverage Volume3.01 million shsMarket Capitalization$5.68 billionP/E Ratio18.55Dividend YieldN/APrice Target$27.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Exelixis MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside56.5% Upside$27.58 Price TargetShort InterestHealthy3.50% of Shares Sold ShortDividend StrengthN/ASustainability-1.63Upright™ Environmental ScoreNews Sentiment0.34Based on 11 Articles This WeekInsider TradingSelling Shares$984,800 Sold Last QuarterProj. Earnings Growth73.58%From $0.53 to $0.92 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.19 out of 5 starsMedical Sector1st out of 1,055 stocksBiological Products, Except Diagnostic Industry1st out of 170 stocks 3.4 Analyst's Opinion Consensus RatingExelixis has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.58, Exelixis has a forecasted upside of 56.5% from its current price of $17.62.Amount of Analyst CoverageExelixis has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.50% of the outstanding shares of Exelixis have been sold short.Short Interest Ratio / Days to CoverExelixis has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Exelixis has recently decreased by 2.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExelixis does not currently pay a dividend.Dividend GrowthExelixis does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExelixis has received a 64.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "VEGFR tyrosine kinase inhibitors", "Mitogen-activated protein kinase (MEK) inhibitors", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Exelixis is -1.63. Previous Next 3.0 News and Social Media Coverage News SentimentExelixis has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Exelixis this week, compared to 6 articles on an average week.Search Interest25 people have searched for EXEL on MarketBeat in the last 30 days. This is an increase of 39% compared to the previous 30 days.MarketBeat Follows26 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 420% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $984,800.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Exelixis is held by insiders.Percentage Held by Institutions84.74% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Exelixis are expected to grow by 73.58% in the coming year, from $0.53 to $0.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exelixis is 18.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Exelixis is 18.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 158.93.Price to Earnings Growth RatioExelixis has a PEG Ratio of 0.59. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioExelixis has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exelixis (NASDAQ:EXEL) StockExelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.Read More Receive EXEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Stock News HeadlinesJanuary 6, 2023 | marketbeat.comFour Undervalued Healthcare Stocks for 2023 (EXEL)These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.January 29, 2023 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 27, 2023 | americanbankingnews.comExelixis (NASDAQ:EXEL) Receives New Coverage from Analysts at Credit Suisse GroupJanuary 25, 2023 | americanbankingnews.comBrokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $27.45January 25, 2023 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Receives $27.45 Average Price Target from AnalystsJanuary 24, 2023 | finance.yahoo.comExelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023January 23, 2023 | americanbankingnews.comExelixis (NASDAQ:EXEL) versus OKYO Pharma (NASDAQ:OKYO) Head-To-Head ReviewFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 22, 2023 | americanbankingnews.comJMP Securities Trims Exelixis (NASDAQ:EXEL) Target Price to $24.00January 20, 2023 | benzinga.comExelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could ContinueJanuary 19, 2023 | finance.yahoo.comExelixis Announces Update on Patent Litigation with MSN LaboratoriesJanuary 18, 2023 | seekingalpha.comExelixis: Building On A BlockbusterJanuary 9, 2023 | finance.yahoo.comExelixis (EXEL) Announces Preliminary Q4 and 2022 ResultsJanuary 8, 2023 | finance.yahoo.comExelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023January 3, 2023 | finance.yahoo.comExelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —January 2, 2023 | thestreet.comExelixis Kidney Cancer Survival Benefit Doesn't Address Competitive QuestionDecember 29, 2022 | finance.yahoo.comIs Exelixis Stock a Buy Now?December 29, 2022 | finance.yahoo.comThis Drug Developer Is My Stock Cure for 2023December 22, 2022 | finance.yahoo.comExelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney CancerDecember 9, 2022 | finance.yahoo.comExelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 StudyDecember 8, 2022 | finance.yahoo.comExelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022December 8, 2022 | finance.yahoo.comExelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and ChemotherapyDecember 2, 2022 | finance.yahoo.comUltragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?December 1, 2022 | finance.yahoo.comWhy Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?November 30, 2022 | finance.yahoo.comExelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022November 12, 2022 | finance.yahoo.comExelixis, Inc. (NASDAQ:EXEL) is a favorite amongst institutional investors who own 82%See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EXEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Company Calendar Last Earnings11/02/2021Today2/01/2023Next Earnings (Confirmed)2/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXEL CUSIP30161Q10 CIK939767 Webwww.exelixis.com Phone(650) 837-7000Fax650-837-8300Employees954Year Founded1994Price Target and Rating Average Stock Price Forecast$27.58 High Stock Price Forecast$42.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+56.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.95 Trailing P/E Ratio18.55 Forward P/E Ratio33.25 P/E Growth0.59Net Income$231.06 million Net Margins18.78% Pretax Margin23.43% Return on Equity13.11% Return on Assets11.07% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.01 Sales & Book Value Annual Sales$1.43 billion Price / Sales3.96 Cash Flow$0.78 per share Price / Cash Flow22.59 Book Value$6.99 per share Price / Book2.52Miscellaneous Outstanding Shares322,560,000Free Float313,207,000Market Cap$5.68 billion OptionableOptionable Beta0.69 Social Links Key ExecutivesMichael M. MorrisseyPresident, Chief Executive Officer & DirectorChristopher J. SennerChief Financial Officer & Executive Vice PresidentDana T. AftabChief Scientific Officer & Executive VP-DiscoveryVicki L. GoodmanChief Medical Officer & Executive Vice PresidentJeffrey J. HessekielSecretary, Executive VP & General CounselKey CompetitorsHalozyme TherapeuticsNASDAQ:HALOBioCryst PharmaceuticalsNASDAQ:BCRXRepligenNASDAQ:RGENNeurocrine BiosciencesNASDAQ:NBIXDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsSargent Investment Group LLCBought 7,600 shares on 1/31/2023Ownership: 0.090%Summit Global InvestmentsBought 38,228 shares on 1/31/2023Ownership: 0.012%AE Wealth Management LLCBought 13,110 shares on 1/31/2023Ownership: 0.004%New York State Common Retirement FundBought 23,590 shares on 1/30/2023Ownership: 0.309%Signaturefd LLCBought 619 shares on 1/30/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions EXEL Stock - Frequently Asked Questions Should I buy or sell Exelixis stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXEL shares. View EXEL analyst ratings or view top-rated stocks. What is Exelixis' stock price forecast for 2023? 9 equities research analysts have issued 12 month target prices for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $42.00. On average, they anticipate the company's stock price to reach $27.58 in the next year. This suggests a possible upside of 56.5% from the stock's current price. View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts. How have EXEL shares performed in 2023? Exelixis' stock was trading at $16.04 on January 1st, 2023. Since then, EXEL stock has increased by 9.9% and is now trading at $17.62. View the best growth stocks for 2023 here. When is Exelixis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023. View our EXEL earnings forecast. How can I listen to Exelixis' earnings call? Exelixis will be holding an earnings conference call on Tuesday, February 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "7374267". How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.19 by $0.07. The biotechnology company had revenue of $328.42 million for the quarter, compared to the consensus estimate of $366.34 million. Exelixis had a trailing twelve-month return on equity of 13.11% and a net margin of 18.78%. During the same period in the prior year, the company posted ($0.10) earnings per share. What guidance has Exelixis issued on next quarter's earnings? Exelixis updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $415.00 million-$415.00 million, compared to the consensus revenue estimate of $414.83 million. What is Michael M. Morrissey's approval rating as Exelixis' CEO? 75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend. What other stocks do shareholders of Exelixis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV). What is Exelixis' stock symbol? Exelixis trades on the NASDAQ under the ticker symbol "EXEL." Who are Exelixis' major shareholders? Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Meditor Group Ltd (2.05%), Stephens Investment Management Group LLC (1.25%), Assenagon Asset Management S.A. (0.63%), Allspring Global Investments Holdings LLC (0.55%), Scout Investments Inc. (0.33%) and New York State Common Retirement Fund (0.31%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View institutional ownership trends. How do I buy shares of Exelixis? Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exelixis' stock price today? One share of EXEL stock can currently be purchased for approximately $17.62. How much money does Exelixis make? Exelixis (NASDAQ:EXEL) has a market capitalization of $5.68 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.95 on an earnings per share basis. How many employees does Exelixis have? The company employs 954 workers across the globe. How can I contact Exelixis? Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300. This page (NASDAQ:EXEL) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.